



CORRECTION

Open Access

# Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy

Ondrej Slaby<sup>1,3\*</sup>, Jana Jancovicova<sup>4</sup>, Radek Lakomy<sup>1</sup>, Marek Svoboda<sup>1</sup>, Alexandr Poprach<sup>1</sup>, Pavel Fabian<sup>2</sup>, Leos Kren<sup>5</sup>, Jaroslav Michalek<sup>3</sup>, Rostislav Vyzula<sup>1</sup>

## Correction

After the publication of this research article [1], the authors noticed an error with Figure 1. Graph D which should have indicated miR-106b expression levels in renal parenchyma (RP) and renal cell carcinomas (RCC), was mistakenly displayed as a duplicate of Graph C. The corrected Figure 1 is provided here.

## Author details

<sup>1</sup>Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Zluty kopec 7, Brno, Czech Republic. <sup>2</sup>Masaryk Memorial Cancer Institute, Department of Oncological and Experimental Pathology, Zluty kopec 7, Brno, Czech Republic. <sup>3</sup>Babak Research Institute, University Cell Immunotherapy Center, Kamenice 5, Brno, Czech Republic. <sup>4</sup>Masaryk University, Faculty of Science, Department of Biochemistry, Kotlarska 2, Brno, Czech Republic. <sup>5</sup>University Hospital Brno, Department of Pathology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Received: 30 July 2010 Accepted: 6 August 2010  
Published: 6 August 2010

## Reference

1. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, Vyzula R: **Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.** *Journal of Experimental & Clinical Cancer Research* 2010, **29**:90.

doi:10.1186/1756-9966-29-105

**Cite this article as:** Slaby *et al.*: Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. *Journal of Experimental & Clinical Cancer Research* 2010 **29**:105.

Submit your next manuscript to BioMed Central  
and take full advantage of:


- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



\* Correspondence: [slaby@mou.cz](mailto:slaby@mou.cz)

<sup>1</sup>Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Zluty kopec 7, Brno, Czech Republic  
Full list of author information is available at the end of the article



**Figure 1**